Burosumab Vs Conventional Therapy in Children with X-linked Hypophosphatemia: Results of the Open-Label, Phase 3 Extension Period.
Leanne M. Ward,Wolfgang Hoegler,Francis H. Glorieux,Anthony A. Portale,Michael P. Whyte,Craig F. Munns,Ola Nilsson,Jill H. Simmons,Raja Padidela,Noriyuki Namba,Hae Cheong,Etienne Sochett,Koji Muroya,Hiroyuki Tanaka,Pisit Pitukcheewanont,Gary S. Gottesman,Andrew Biggin,Farzana Perwad,Angel Chen, John Lawrence Merritt,Erik A. Imel JBMR PLUS（2024）
关键词
burosumab,FGF23,phosphate,rare disease,x-linked hypophosphatemia
AI 理解论文
溯源树
样例
